Clinical review report: Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.) indication: moderate-to-severe atopic dermatitis (AD)
The objective of this review was to perform a systematic review of the beneficial and harmful effects of dupilumab (Dupixent) for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those the...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, July 2018
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review was to perform a systematic review of the beneficial and harmful effects of dupilumab (Dupixent) for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable |
|---|---|
| Physical Description: | 1 PDF file (87 pages) illustrations |